AnaptysBio, Inc (ANAB) stock
ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026Market cap $1.73BP/E –Yield –
AnaptysBio operating margin
Operating margin is operating income as a percentage of revenue.
AnaptysBio's operating margin for the twelve months ending Sep 30, 2026 was 155.6%. For fiscal 2025 it was 96.7%, against 72.5% the year before. The highest annual figure on record is 96.7% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 96.7% | +24.2 |
| FY2024 | Dec 31, 2024 | 72.5% | +1030.7 |
| FY2023 | Dec 31, 2023 | -958.3% | +161.1 |
| FY2022 | Dec 31, 2022 | -1119.4% | −1029.5 |
| FY2021 | Dec 31, 2021 | -89.9% | −58.1 |
| FY2020 | Dec 31, 2020 | -31.8% | +1311.1 |
| FY2019 | Dec 31, 2019 | -1342.9% | −8.5 |
| FY2018 | Dec 31, 2018 | -1334.4% | −1046.6 |
| FY2017 | Dec 31, 2017 | -287.8% | −269.7 |
| FY2016 | Dec 31, 2016 | -18.1% | +0.8 |
| FY2015 | Dec 31, 2015 | -18.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 65.7% | −35.5 |
| Q2 FY2026 | Jun 30, 2026 | 243.6% | +361.1 |
| Q1 FY2026 | Mar 31, 2026 | -135.5% | −36.4 |
| Q4 FY2025 | Dec 31, 2025 | 227.2% | −170.5 |
| Q3 FY2025 | Sep 30, 2025 | 101.2% | +177.1 |
| Q2 FY2025 | Jun 30, 2025 | -117.5% | +250.0 |
| Q1 FY2025 | Mar 31, 2025 | -99.2% | +488.7 |
| Q4 FY2024 | Dec 31, 2024 | 397.6% | +865.5 |
| Q3 FY2024 | Sep 30, 2024 | -75.8% | +1061.4 |
| Q2 FY2024 | Jun 30, 2024 | -367.5% | +792.7 |
| Q1 FY2024 | Mar 31, 2024 | -587.8% | +2643.7 |
| Q4 FY2023 | Dec 31, 2023 | -467.9% | −86.4 |
| Q3 FY2023 | Sep 30, 2023 | -1137.2% | +1154.6 |
| Q2 FY2023 | Jun 30, 2023 | -1160.2% | +1125.9 |
| Q1 FY2023 | Mar 31, 2023 | -3231.5% | +41.6 |
| Q4 FY2022 | Dec 31, 2022 | -381.5% | +2700.3 |
| Q3 FY2022 | Sep 30, 2022 | -2291.8% | −2259.4 |
| Q2 FY2022 | Jun 30, 2022 | -2286.1% | −2284.3 |
| Q1 FY2022 | Mar 31, 2022 | -3273.1% | −3109.8 |
| Q4 FY2021 | Dec 31, 2021 | -3081.8% | −3137.4 |
| Q3 FY2021 | Sep 30, 2021 | -32.4% | +36.0 |
| Q2 FY2021 | Jun 30, 2021 | -1.8% | +740.2 |
| Q1 FY2021 | Mar 31, 2021 | -163.3% | +369.9 |
| Q4 FY2020 | Dec 31, 2020 | 55.6% | +393.3 |
| Q1 FY2020 | Mar 31, 2020 | -68.4% | +170.0 |
| Q4 FY2019 | Dec 31, 2019 | -741.9% | −705.4 |
| Q2 FY2019 | Jun 30, 2019 | -533.1% | −417.9 |
| Q3 FY2018 | Sep 30, 2018 | -337.7% | – |
| Q4 FY2017 | Dec 31, 2017 | -238.4% | – |
| Q2 FY2017 | Jun 30, 2017 | -36.5% | – |
| Q4 FY2016 | Dec 31, 2016 | -115.3% | – |
See a number that looks wrong?